Publish Time: 2023-11-21 Origin: Site
Toronto, Nov. 21th – Dinfectome Inc., announced on Tuesday that its DIFSEQ-200 sequencer gained approval from the Chinese National Medical Products Administration (NMPA) on November 8, 2023.
The DIFSEQ-200 is a compact and flexible desktop sequencer that employs a combination of probe-anchored synthesis and DNA nanoball sequencing technology. This sequencer can pair with an automated pre-processing instrument, nucleic acid extractor, automated library preparation, and GENSISTM bioinformatics analyzer to conduct in-hospital NGS testing according to clinical needs, providing personalized reports to guide the use of precision drugs.
With its high sequencing quality (Q30≥85%), multiple read lengths, various data outputs (10-150G), and compatibility with different sample types (tissue, peripheral blood, sputum, and cerebrospinal fluid), DIFSEQ-200 is suitable for comprehensive clinical applications, including prenatal screening, tumor variant detection, and pathogen identification.
Established in 2018, Dinfectome is a high-tech company dedicated to the research, development, and service of clinical molecular testing for pathogenic microorganisms. Thus far, Dinfectome has established five medical testing centers and collaborates with over 1,500 clinical experts across more than 700 core hospitals.
"The approval of the DIFSEQ-200 sequencer marks a significant milestone for the Dinfectome. The accompanying automated workflow greatly increases our service efficiency, enabling us to enhance collaboration with our partners in China," said Minchao Zhao, Co-founder & COO of Dinfectome, in a statement.